These updated guidelines are based on a first edition of the World Federation of Societies of
Biological Psychiatry Guidelines for Biological Treatment of Schizophrenia published in …

Patients with schizophrenia often fail to respond to an initial course of therapy. This study
systematically reviewed the societal and economic burden of treatment-resistant …

Multicentre trials in patients with schizophrenia confirm that olanzapine is a novel
antipsychotic agent with broad efficacy, eliciting a response in both the positive and negative …

A systematic approach to the evaluation and characterization of treatment resistance in
schizophrenia has become increasingly important since the introduction of the second …

Olanzapine, a thienobenzodiazepine derivative, is a second generation (atypical)
antipsychotic agent which has proven efficacy against the positive and negative symptoms …

The atypical antipsychotics risperidone, olanzapine, quetiapine, ziprasidone, and
aripiprazole have become first-line treatment for schizophrenia because they reduce the …

Background: The treatment of schizophrenic patients who fail to respond to adequate trials
of neuroleptic drugs is a major challenge. Clozapine has been one treatment option; …

The first compounds showing efficacy in the treatment of schizophrenia and other psychotic
disorders was chlorpromazine, an anti-histaminic compound casually observed to possess …

The pharmacologic treatment of schizophrenia remains a critical component in the short-and
long-term management of this disease. Considerable progress has been made in …

Background: There is relatively little information regarding the efficacy of newer atypical
antipsychotic drugs for patients with schizophrenia who are treatment-resistant to …